You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
邁威生物(688062.SH):用於治療晚期惡性腫瘤的注射用8MW2311的臨牀試驗申請獲受理
格隆匯 02-14 16:10

格隆匯2月14日丨邁威生物(688062.SH)公佈,近日公司收到國家藥品監督管理局核准簽發的受理通知書注射用8MW2311的臨牀試驗申請獲得受理

注射用8MW2311是一種聚乙二醇偶聯人白介素-2免疫激動劑,用於治療晚期惡性腫瘤。8MW2311注射入體內後,可刺激下游轉錄因子STAT5磷酸化,有效激發殺傷性T淋巴細胞CD8+T細胞的增殖,從而發揮藥效。臨牀前研究結果顯示,8MW2311在腫瘤組織中富集並具有偏好地激活CD8+T細胞的藥理作用,在多種腫瘤模型中顯示出持續有效的抑瘤作用,並且與免疫檢查點藥物(如抗PD-1抗體)聯用能表現出顯著性增強的協同抑瘤效果。進入臨牀試驗後,公司將探索注射用8MW2311在晚期惡性腫瘤中的治療價值。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account